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Accurate in-vitro component-based diagnosis will allow
clinicians to focus their efforts toward complex issues
such as disease severity and reactive dose evaluation as
well as establishing effective eviction measures. However
to achieve this, clinical utility of component-resolved
peanut allergy testing must be rigorously evaluated. In
this pilot study, we compared performances of 2 compo-
nent-resolved peanut allergy assays from Hycor® [H]
and Thermo Scientific® [T] that are based on recombi-
nant allergens (rAra h 1 [H/T], rAra h 2 [H/T], rAra h
3 [H/T], rAra h 6 [H], rAra h 7 [H], rAra h 8 [H/T] and
rAra h 9 [H/T]). IgE reactivity to each allergen was
measured in 34 clinically characterized patients: 26 pea-
nut-allergic and 8 atopic subjects from Eastern and
Northern France. Total peanut extract assay [T] yielded
low performances even with a 0.35 kU/L cut-off (sensi-
tivity: 92%, specificity: 25%). Quantifications of IgE to
rAra h 1, rAra h 2 and rAra h 3 show a strong correla-
tion between the two manufacturers (rAra h 1: r2 =
0.85, p < 10-3 ; rAra h 2: r2 = 0.96, p < 10-3; rAra h 3:
r2 = 0.90, p < 10-3) and achieve the same level of perfor-
mances independently of the allergen source. Among
these three assays, rAra h 2 [H/T] yielded a sensitivity of
85% and a specificity of 100% with a 0.35 kU/L cut-off.
The rAra h 6 assay is available from Hycor® only and
yielded a sensitivity of 92% and a specificity of 100%
using the same cut-off, i.e. 24/26 peanut allergic patients
are positive for rAra h 6. The IgE from the 2 undiagnosed
patients do not react with any of the other recombinant
from any sources. Neither Hycor® nor Thermo Scienti-
fic® rAra h 8 assays are clinically useful for peanut allergy
diagnosis in spite of their specificity differences at 50%
and 25% respectively. Thermo Scientific® rAra h 9 assay
was not clinically useful with no positive sample detected.
Hycor® rAra h 9 assay detected 2 of the 26 peanut aller-
gic patients without reactivity in the atopic patients (spe-
cificity: 12%, sensitivity: 100%). This is consistent with
the low prevalence of Ara h 9 sensitisation in Northern
Europe. This study suggests the possibility of improving
the clinical utility of molecular component assays by sub-
stituting rAra h 6 to rAra h 2. It also introduces rAra h 9
as a novel component that might be a significant clinical
value in countries outside Northern Europe. This will be
evaluated in multicenter studies.
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